Active, not recruitingPhase 3NCT04523272
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Studying Catastrophic antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- TQB2450(drug)
- Enrollment
- 528 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2020 – 2025
Study locations (30)
- The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Chinese PLA General Hospital, Beijing, Beijing Municipality, China
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Fujian Provincial Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- First Hospital of Lanzhou University, Lanzhou, Gansu, China
- Sun Yat-sen of Cancer Center, Guangzhou, Guangdong, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04523272 on ClinicalTrials.govOther trials for Catastrophic antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07458984FMT Capsules for rCDIHelsinki University Central Hospital
- RECRUITINGPHASE1NCT07297199A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55Biogen
- RECRUITINGPHASE3NCT07165951Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNANCT07561333Comparing ACB+IPACK and ACB+BiFeS Block Combinations for Analgesia in Total Knee ArthroplastyHitit University
- RECRUITINGPHASE2, PHASE3NCT06841679Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaBeijing Biostar Pharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07044271A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsEli Lilly and Company
- RECRUITINGPHASE1NCT06943677A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant TumorsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT06822946Zhibitai Capsules for the Treatment of Primary HyperlipidemiaChengdu Diao Jiuhong Pharmaceutical Factory